Minakem gets $18M from parent Minafin to upgrade French manufacturing site

CMO Minakem to spend $18 million to upgrade capacity at its API plant in Dunkirk, France.

Minakem, a CMO, is getting $18 million from its parent company, Belgium-based Minafin, to upgrade and increase capacity at its manufacturing plant in Dunkirk, France.

The company said it plans to use the investment to set up a new production line, increase production capacity and upgrade other operations at the site. The improvements are expected to increase production value to a total capacity of 148m3.

The upgrades are in response to several new innovations and molecules coming to market, which is driving demand for more production capacity in Europe, the company said.


Innovative and Flexible Solutions for an End-to-End Patient-Centric, Lean Supply Chain

The trend toward crafting patient-centric clinical trials hold great promise in supporting patients’ willingness and ability to participate in important clinical research. This webinar will explore how recent innovations in forecasting, supply pooling, decentralized processing, labeling, demand-led supply and direct-to-patient distribution are converging to create a next-generation clinical supply chain that is flexible, lean and most importantly patient-centric.

“It fits into our ‘Jump 21’ strategy and follows Minafin’s objective to increase overall production capacity at Minakem’s sites,” Thierry van Nieuwenhove, Minakem’s chief executive, said in a statement. “This will also enable us to better respond to growing market needs and will undoubtedly contribute to the expansion of our product and service offering and to our growth.”

The engineering phase of the project at the site, which was purchased from AstraZeneca 2009, is already underway. The upgrades are expected to be operational by May 2019, pending regulatory approvals planned for earlier that year.



Suggested Articles

Bluebird Bio says the launch of Zynteglo, its first gene therapy, will not occur until 2020 while it tightens up its manufacturing processes.

Catalent is buying a site in Italy from Bristol-Myers Squibb that handles biologics along with old-school solid dose production.

Here is some more manufacturing news from the week.